【摘要】 目的　探讨bcr/abl融合基因检测在慢性粒细胞白血病 (CML)治疗效果及微小残留病灶监测方面的价值。方法　应用RT -nested -PCR方法定期检测异基因造血干细胞移植 (allo -HSCT)治疗慢性粒细胞性白血病患者前后融合基因表达情况。结果　异基因造血干细胞移植患者在移植后 1个月到 2个月bcr/abl融合基因转阴率为 76 % ,10 0天转阴率达 88%。结论　RT -nestedPCR方法检测bcr/abl融合基因可以作为临床诊断、判定预后的指标 ,适用于微小残留病变的监测更多还原

【Abstract】 Objective To investigate the value of RT-nested-PCR in detecting bcr/abl fasin gene in monitoring the response to therapy in chronic myeloid leukenia patient. Methods Monitoring the expression of bcr/abl fusion gene by using RT-nested-PCR in patient chronic myeloid leukemina before and after treatment by allogeneic hematopoietic stem cell transplantation(allo-HSCT).Results 76% turned to be negative at 1 months to 2 months post allo-HSCT.88% achieved genetic complete remission in 100 days.Conclusion Monitoring the bcr/abl fusion gene by RT-nested-PCR can be used to evalute the efficacy of the therapy and detect the minimal residual disease(MRD).更多还原